Physician profile
Sarah E Joyner
NPI 1205047628
$612.35
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2021: $22.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.34 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.69 | 2019 | |
| Pfizer INC. | $59.38 | 2019 | |
| Astellas Pharma US INC | $51.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $46.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.85 | 2019 | |
| Braemar Manufacturing, LLC | $25.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Joyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.